Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 168 participants.

Also called NCT05366101

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose supportive care
Phase
Phase 2/3
Enrolled
  • 168 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05366101
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05366101. Randomized; no masking; primary purpose supportive care. Start 2019-04-01 (actual); primary completion 2022-02-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy
Acronym
SILICOFCM
Condition
Hypertrophic Cardiomyopathy
Intervention (Drug)
Sacubitril/Valsartan
Intervention (Behavioral)
Lifestyle
Lead sponsor
Newcastle-upon-Tyne Hospitals NHS Trust (class: other)
Collaborator
University Hospital Regensburg (class: other)
Collaborator
Assistance Publique - Hôpitaux de Paris (class: other)
Collaborator
Azienda Ospedaliero-Universitaria Careggi (class: other)
Collaborator
Institute of Cardiovascular Diseases, Vojvodina (class: other)

Record details

Record id
cardio:ct-nct05366101
Content hash
804e3cad8d489098bef00ff4e37d9b43c574363f4246da39317937e103566b33